ZEVRA THERAPEUTICS, INC. — Form 8-K
Filed August 5, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 48/100
What the filing says
Zevra reported Q2 2026 net revenue of $39.7M (vs. $25.9M in Q2 2025), with MIPLYFFA generating $30.2M. The company enrolled 184 total NPC prescription forms since launch with 69% market access; 132 patients in global Expanded Access Program. Cash position: $260.2M as of June 30, 2026. Net income Q2 2026: $8.8M ($0.14 per share); excludes $6.4M noncash warrant/CVR adjustments. Celiprolol Phase 3 trial enrolled 66 patients with 3 confirmed events.
Why this rating
Strong revenue growth and positive net income are encouraging; $260.2M cash (57% of market cap) provides runway. However, absolute revenue ($39.7M quarterly) and patient enrollment (184 cumulative prescriptions) remain modest for a commercial-stage rare-disease player. Pipeline progress (celiprolol 66 enrolled) is incremental. Material but not transformational.
See more from August 5, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.